A single dose of the cell therapy candidate zorpocabtagene-autoleucel (zorpo-cel) led to rapid, durable symptom relief in a woman with severe, hard-to-treat cold agglutinin disease (CAD) in a rare combination with two other autoimmune disorders, a case study reported. The woman had been dependent on blood transfusions for…